Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1826

Shown on this page

Current sort

Live official records

Conditions: Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions: C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau; Diagnostic Test
Lead sponsor: Jennifer Whitwell; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Immunoglobulin A Nephropathy
Interventions: Sibeprenlimab 400 mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more

Conditions: Ovarian Cancer
Interventions: Gleolan; Drug
Lead sponsor: NX Development Corp; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Jacksonville, Florida • Annapolis, Maryland + 8 more

Conditions: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Interventions: TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin; Combination Product
Lead sponsor: TORL Biotherapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Fullerton, California • Irvine, California • Los Angeles, California + 3 more

Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation, Transplant-ineligible 2nd Line DLBCL
Interventions: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine; Biological · Drug
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more

Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions: Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine; Radiation · Drug
Lead sponsor: Laura M. Spring, MD; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Epilepsy; Seizure
Interventions: Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring, Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autosomal Dominant Leukodystrophy
Interventions: nL-LMNB1-001; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 51 Years to 51 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Conditions: Multiple Myeloma
Interventions: Etentamig (ABBV-383); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness, ICUAW, Sarcopenia, Secondary Sarcopenia
Interventions: Electrical Muscle Stimulation System; Device
Lead sponsor: Health Discovery Labs; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Rochester, Minnesota • Austin, Texas

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

Imaging Studies in Corticobasal Syndrome

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

DALY II USA/ MB-CART2019.1 for DLBCL

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Thalamus Seizure Detection With a Deep Brain Stimulator System

Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients

About this Mayo Clinic institution page